Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Friday, November 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

SmartLab Exchange Europe 2027 Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 6

Pathos AI Partners with BMS and Tempus to Advance Alzheimer’s Drug Research

Oct 28, 2026
Pathos AI has announced strategic collaborations with Bristol Myers Squibb (BMS) and Tempus AI to use artificial intelligence (AI) to advance drug development for Alzheimer’s disease…
Read More...

Octant Wins FDA Orphan Drug Status for Retinitis Pigmentosa Drug

Oct 28, 2026
Octant has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for OCT-980, an investigational oral drug being developed to treat retinitis pigmentosa, a…
Read More...

Regeneron Extends $270M Deal to Supply Ebola Treatment Inmazeb

Oct 28, 2026
Regeneron Pharmaceuticals has extended its agreement with the US government to provide additional supplies of Inmazeb, an antibody-based treatment for Ebola disease. The expanded…
Read More...

Pfizer’s Talzenna Combination Wins FDA Approval for Earlier Prostate Cancer

Oct 28, 2026
Pfizer has received US Food and Drug Administration (FDA) approval to expand the use of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) for men with a specific type of…
Read More...

Astellas and Audax Sign Up to $1.34B Cancer Drug Deal

Oct 28, 2026
Astellas Pharma and Australian biotechnology company Audax Biosciences have entered into an exclusive option and license agreement for DAX-044, an investigational cancer immunotherapy…
Read More...

Arrowhead’s REDEMPLO Gains NHS Access for Rare Cholesterol Disorder

Oct 27, 2026
Arrowhead Pharmaceuticals has announced that adults living with familial chylomicronaemia syndrome (FCS) in England and Wales will have access to REDEMPLO (plozasiran), a new treatment…
Read More...

Regeneron’s Libtayo Shows Greater Survival Benefit in Skin Cancer

Oct 26, 2026
Regeneron Pharmaceuticals has reported new long-term data showing that Libtayo (cemiplimab) may help reduce the risk of death in patients with high-risk cutaneous squamous cell…
Read More...

Astellas’ Veoza Menopause Drug Application Accepted in China

Oct 26, 2026
Astellas Pharma has announced that China’s National Medical Products Administration (NMPA) has accepted a new drug application for Veoza (fezolinetant) 45 mg, a non-hormonal treatment…
Read More...

Lunit and Summit Therapeutics Partner on AI-Powered Cancer Research

Oct 26, 2026
Lunit and Summit Therapeutics have entered into a research agreement to use artificial intelligence (AI) to study the tumor microenvironment and support the development of new cancer…
Read More...

ScionxBio and Sanofi Partner to Develop Longer-Lasting RNA Medicines

Oct 23, 2026
ScionxBio has entered into a worldwide research collaboration and licensing agreement with Sanofi to develop longer-lasting RNA-based medicines. The partnership will use ScionxBio’s…
Read More...
Previous 1 … 4 5 6 7 8 … 966 Next
Oligonucleotide-based Therapeutics Summit
LEAP HR: Life Sciences Europe
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Antigen-Specific Immune Tolerance Summit
7th Operationalize Expanded Access Programs Summit
Viral Vector Process Development & Manufacturing Summit
SmartLab Exchange Europe 2027
8th RNAi-Based Therapeutics Summit
17th World ADC London
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • OBI Pharma Signs $2 Billion ADC Deal with Novartis
  • Erasca and Bristol Myers Squibb Partner on Pancreatic Cancer Treatment
  • GSK Wins FDA Approval for Nelkarmi in Advanced Lung Cancer
  • OXB Partners with Aura Biosciences for Phase 3 Cancer Drug Development
  • Skylark Bio Advances Hearing Loss Gene Therapy to Younger Children

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Cell Therapy Safety in Autoimmune Disease

7th Operationalize: Expanded Access Programs Summit East…

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.